-
Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. et al DC CAFC
- 1:13-cv-01874
- D. Del.
- Judge: Colm F. Connolly
- Filed: 11/08/2013
- Closed: 10/17/2019
- Latest Docket Entry: 10/17/2019
- PACER
- Docket updated daily
1
Plaintiff
11
Defendants
1
Accused
Product
2
Patents-in-Suit
2,170
Days in
Litigation
-
Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. et al DC CAFC
- 1:13-cv-01874
- D. Del.
- Judge: Colm F. Connolly
- Filed: 11/08/2013
- Closed: 10/17/2019
- Latest Docket Entry: 10/17/2019
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 20 |
The lyophilized compound D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Enforceable and Valid
Entry 163 Entry 161 Entry 157 Entry 173 Entry 175 Entry 169 |
| 31 |
The method of claim 23, wherein the compound of formula (1) is D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Enforceable and Valid
Entry 163 Entry 161 Entry 157 Entry 173 Entry 175 Entry 169 |
| 49 |
A lyophilized cake comprising the compound of claim 20.
|
Enforceable and Valid
Entry 163 Entry 161 Entry 157 Entry 173 Entry 175 Entry 169 |
| 53 |
The method of claim 31 further comprising (c) reconstituting the lyophilized mixture with a pharmaceutically-acceptable carrier.
|
Enforceable and Valid
Entry 163 Entry 161 Entry 157 Entry 173 Entry 175 Entry 169 |
-
Infringement
Apotex Corporation
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injectionGeneric bortezomib for Injection, 3.5 mg/vial | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 148Entry 175 |
Apotex Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injectionGeneric bortezomib for Injection, 3.5 mg/vial | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 148Entry 175 |
Cadila Healthcare Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 157
|
QILU Pharmaceutical Company Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 169
|
Qilu Pharma, Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 169
|
Zydus Pharmaceuticals (USA) Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 157
|
